Topic of the Month on ModernWeight: Redefining Weight Management Together: Let's Talk Stigma and Solutions
Head to the Social Hub to share your success story or learn about others.
AOMs in the News
This Week's Featured Post
Muscle Loss Risks with GLP-1 Therapy – What You Need to Know
Link: Medical Dialogues
This week’s featured post covers an important Lancet report highlighting a potential side effect of GLP-1 receptor agonists (GLP-1 RAs) gaining attention: muscle loss associated with weight reduction. While these medications are effective in helping individuals lose weight, the potential for skeletal muscle loss has prompted discussions about the broader impacts of GLP-1 RAs on overall physical health. Skeletal muscle mass is critical, particularly as it plays a key role in mobility, metabolism, and overall strength.
The findings urge healthcare providers to monitor not only weight loss but also muscle retention, emphasizing a balanced approach that supports both fat loss and muscle preservation. Experts suggest incorporating muscle-strengthening exercises and adequate protein intake as a proactive approach to counterbalance muscle loss while patients undergo GLP-1 RA treatment. This information provides insights for both patients and providers to make informed choices about weight management using these medications.
Why It Matters: Understanding the potential for muscle loss while on GLP-1 therapies ensures that patients and healthcare providers can take steps to preserve muscle mass during treatment, balancing weight loss goals with overall health. Maintaining muscle strength not only supports long-term wellness but also enhances the quality of life and functionality in everyday activities.
The use of GLP-1 Drugs for Obesity Doubled Over the Past Year
Link: Medical Dialogues
Researchers from Brigham and Women’s Hospital and Harvard have published data showing a sharp increase in the use of GLP-1 RAs for obesity, with use rates doubling in the last year. This trend is coupled with a noticeable 25.6% decline in bariatric surgeries, highlighting a shift toward pharmacological treatments for obesity.
The analysis, based on insurance data from over 17 million adults, reflects a growing preference for medication-based weight management solutions as they become more accessible. This shift represents changing patient choices and a broader societal move towards accessible, less invasive options for managing weight and obesity.
Why It Matters: With obesity rates on the rise, effective and accessible solutions for weight loss are more critical than ever. Understanding the impact of GLP-1 RAs on public health highlights their role in providing non-surgical weight management, potentially reducing the need for more invasive procedures.
Trends in Obesity Treatment: A Shift from Surgery to GLP-1 Medications
Link: HealthDay
A recent report has shown a significant trend in obesity treatment: a decrease in bariatric surgeries alongside a rise in GLP-1 RA prescriptions. This shift could mean fewer patients opting for invasive procedures, with medications like semaglutide offering similar benefits in weight loss management.
The research points to potential advantages for patients seeking less invasive methods, though it also highlights the importance of evaluating both the efficacy and risks of long-term medication use. This trend may transform how obesity is treated, emphasizing the role of pharmaceuticals in managing chronic weight conditions.
Why It Matters: This shift could lead to wider access to obesity treatment without the risks associated with surgery, opening up new pathways for patients. However, as the popularity of GLP-1 medications grows, so does the need for responsible prescribing and monitoring to ensure balanced, safe health outcomes.
New GLP-1 Guidance for Patients Undergoing Surgery
Link: News-Medical
Updated guidelines now provide clarity on managing GLP-1 RA use for patients undergoing surgery. Issued by several prominent health organizations, the guidance advises that most patients may safely continue GLP-1 RAs before surgery, though high-risk patients should follow specific dietary and anesthesia precautions.
The guidance comes in response to concerns about delayed gastric emptying, a known side effect of GLP-1 RAs that could increase surgical risks. Providers are now better equipped with information to make case-by-case decisions, enhancing patient safety around surgical procedures.
Why It Matters: Ensuring the safe use of GLP-1 RAs during surgical procedures is vital, as it allows patients to continue necessary medications without compromising surgical outcomes. This guidance fosters a more nuanced approach to patient care.
Telehealth Programs for GLP-1 Therapy Yield Promising Results
Link: Wiley Online Library
A 12-month study conducted by WW Clinic (formerly Weight Watchers) shows promising outcomes for telehealth-based obesity treatment using GLP-1 medications. Tracking 53,590 patients, the study found sustained weight loss and manageable side effects, reflecting a successful integration of telehealth in obesity care.
Participants received personalized treatment plans, including medication support and regular check-ins with healthcare providers. The findings suggest that telehealth models may provide accessible and effective obesity treatment, with the potential to expand remote care options for weight management.
Why It Matters: Telehealth’s effectiveness in managing obesity demonstrates its value in increasing accessibility and convenience for patients. Such models could support larger populations in achieving their weight loss goals while maintaining medical oversight.
---
Expert Tweet of the Week
From @GLP1_News
"FDA removes Novo's Wegovy from shortage list, marking end of semaglutide supply rout in US | Fierce Pharma"
Related Article: Fierce Pharma
---
Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.
Want to receive this newsletter in your inbox weekly? Create a profile!
Comments